Targeted therapies in breast cancer / Harold J. Burstein.

By:

Burstein, Harold J

Material type: Text

text

Media type:

computer

Carrier type:

online resource

ISBN:

9780199749751
0199749752
1280699094
9781280699092
9786613676061
6613676063

Subject(s): Genre/Form:

Additional physical formats: Print version:: Targeted therapies in breast cancer.DDC classification:

616.99449061 22

LOC classification:

RC280.B8 B87 2011eb

NLM classification:

WP 900

Online resources:

Click here to access online

Contents:

Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References.

Summary: The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th.

Item type:

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Home library	Collection	Call number	Materials specified	Status	Date due	Barcode
Electronic-Books	OPJGU Sonepat- Campus	E-Books EBSCO			Available

Includes bibliographical references.

Print version record.

The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th.

English.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide

There are no comments on this title.

to post a comment.